Two sets of books for AI-driven pharmaceutical research and development

▤ Summary

This article examines the widening valuation gap between AI drug discovery companies in private and public markets. It contrasts Isomorphic Labs’ large financing and high private-market valuation with Insilico Medicine and Recursion’s much lower public-market valuations. The piece argues that these companies are evolving from traditional biotech models toward TechBio platforms built around AI infrastructure, data systems, and scientific workflows. It also notes that partnerships with major technology vendors and ecosystem players are becoming more important as AI capabilities mature. In the long run, the article expects the market to reprice these companies more like software and platform businesses than classic biotech firms.

▦ Linked Companies

NVIDIA Corporation

$1B+

Insilico Medicine

$25M to $50M

Recursion Pharmaceuticals, Inc.

$50M to $100M